Prostate Cancer

These tests will be based on ExonHit's expertise in identifying specific genetic signatures from alternative RNA splicing associated with diseases and will capitalise on bioMirieux's know-how in developing and commercialising diagnostic tests.

The scientific data demonstrated that the panel of genetic signatures identified by ExonHit could clearly distinguish healthy women from those with early stage breast cancer.

A total of 54 genes were able to correctly classify, with accuracy of 86.7 per cent, a group of 92 women, 55 with stage I/II breast cancer and 37 healthy women.

"These results provide proof that by using a characterised set of molecular markers in blood it can be possible to develop a diagnostic test for breast cancer," said Bruno Tocqui, President of the Management Board of ExonHit Therapeutics.

The ExonHit and bioMerieux collaboration in breast cancer diagnostics was initiated in 2003 and was extended in 2005 for six additional years expanding the agreement to other cancers.

In return for its researc...

Read more...